QPI-1007治疗急性非动脉炎性前部缺血性视神经病变的随机假手术对照2/3期试验
这项国际多中心双盲假手术对照随机试验纳入725例急性单侧非动脉炎性前部缺血性视神经病变(NAION)患者,评估玻璃体腔注射QPI-1007的安全性及疗效。6个月时多剂量组与假手术组在BCVA下降≥15字母比例上无差异,但基线BCVA≤60字母(≤20/63)亚组中1.5 mg×3组和3.0 mg×3组BCVA下降10字母比例显著低于假手术组(P=0.045和P=0.0104),且该亚组7 dB视野平均偏差丢失得到显著预防(P=0.023)。
要点
- 主要终点未达到:6个月时多剂量组与假手术组BCVA下降≥15字母比例无差异。
- 基线BCVA≤60字母亚组中,1.5 mg×3组和3.0 mg×3组BCVA下降10字母比例显著低于假手术组(P=0.045和P=0.0104)。
- 基线BCVA≤60字母亚组中,7 dB视野平均偏差丢失得到显著预防(P=0.023)。
核心结论
- 玻璃体腔注射QPI-1007治疗急性NAION耐受性良好。
- 虽然主要结局指标未达到,但在基线BCVA为20/63或更差的亚组中观察到保留视力的显著效果。
研究设计与样本
- 国际、多中心、双盲、假手术对照随机试验。
- 纳入725例在视觉症状出现14天内入组的急性单侧NAION患者。
- 按1:1:1:1:1比例随机分配至5个治疗组(预设中期分析后减至3个治疗组):单次1.5 mg玻璃体腔注射、单次3 mg玻璃体腔注射、每两月一次共3次1.5 mg玻璃体腔注射、每两月一次共3次3.0 mg玻璃体腔注射或假手术注射。
主要发现
- 6个月时,多剂量组与假手术组相比,BCVA下降≥15字母的参与者比例无差异。
- 基线BCVA≤60字母(Snellen等效≤20/63)亚组分析显示,1.5 mg×3组(P=0.045)和3.0 mg×3组(P=0.0104)BCVA下降10字母的比例显著低于假手术组。
- 基线BCVA≤60字母的参与者中,7 dB视野平均偏差丢失得到显著预防(P=0.023)。
- 除玻璃体腔注射的预期副作用外,组间不良事件频率无显著差异。
关键数值与推荐
- 主要终点为安全性和第1天至第6个月BCVA下降≥15个早期治疗糖尿病视网膜病变研究字母的比例。
- 次要结局指标为第1天至第6个月BCVA平均变化和视野敏感度平均变化。
- 基线BCVA≤60字母亚组中,1.5 mg×3组BCVA下降10字母比例显著低于假手术组(P=0.045)。
- 基线BCVA≤60字母亚组中,3.0 mg×3组BCVA下降10字母比例显著低于假手术组(P=0.0104)。
- 基线BCVA≤60字母亚组中,7 dB视野平均偏差丢失得到显著预防(P=0.023)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nonarteritic anterior ischemic optic neuropathy (NAION), the most common acute optic neuropathy in patients > 50 years of age, has no proven therapy. We report the results of a phase 2/3 clinical trial studying the safety and efficacy of intravitreal injection of QPI-1007, a small interfering RNA against the apoptotic protein caspase 2, in participants with acute-onset NAION. DESIGN: International, multicenter, double-masked, sham-controlled randomized trial. PARTICIPANTS: Seven hundred twenty-five participants with acute unilateral NAION enrolled within 14 days of visual symptoms. METHODS: Intravitreal injection of QPI-1007 into the study eye of a single dose, multiple dose, or sham injection. Participants were randomized in a 1:1:1:1:1 ratio to 5 treatment groups (down to 3 treatment groups after a preplanned interim analysis): 1 intravitreal injection of 1.5 mg, 1 intravitreal injection of 3 mg, 3 bimonthly intravitreal injections of 1.5 mg each, 3 bimonthly intravitreal injections of 3.0 mg each, or sham injection. MAIN OUTCOME MEASURES: The primary end points were safety and the proportion of patients losing at least 15 Early Treatment Diabetic Retinopathy Study letters of best-corrected visual acuity (BCVA) between day 1 and month 6. Secondary outcome measures were mean change in BCVA and mean change in visual field (VF) sensitivity from day 1 to month 6. RESULTS: At 6 months, no difference was found in the proportion of participants who lost 15 letters or more of BCVA in the multidose groups compared with the sham group. A subanalysis of participants with baseline BCVA of ≤ 60 letters or fewer (Snellen equivalent, ≤ 20/63) demonstrated a significantly lower proportion losing 10 letters of BCVA (P = 0.045 for the 1.5 mg × 3 group and P = 0.0104 for the 3.0 mg × 3 group) compared to sham. Significant prevention of 7-dB loss of VF mean deviation was seen in participants with ≤ 60 letters or fewer at baseline (P = 0.023). No significant differences were found in the frequency of adverse events between groups other than expected side-effects of intravitreal injection. CONCLUSIONS: Intravitreal injection of QPI-1007 in eyes with acute NAION was well tolerated. Although the primary outcome measure was not met, significant effects on preserving vision were observed in the subgroup of participants with baseline BCVA of 20/63 or worse. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Levin LA, Bhatti MT, Klier S, et al. A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2025. PMID: 40816607. doi:10.1016/j.ophtha.2025.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。